Filing excerpt
On April 30, 2026, the Company also announced it appointed Aaron Bloomer, age 40, as Chief Financial Officer, effective May 4, 2026.
sec.gov/Archives/edgar/data/943819/000119312526197282/d50610d8k.htmRead the full source
ResMed8-K: Restructuring
ResMed appoints new CFO Aaron Bloomer, effective May 4, 2026, replacing retiring CFO.
What happened
Mr. Bloomer's background at large corporations like Baxter and 3M suggests he may drive strategic shifts or technology investments in ResMed's finance function.
Source
Other signals in this filing (3)
- Governance changeResMed appoints new CFO Aaron Bloomer, effective May 4, 2026, replacing retiring Brett Sandercock.Governance change
- CFO changeResMed appoints new CFO Aaron Bloomer, effective May 4, 2026, with a $3.3M equity grant.CFO change
- Chief accounting officer changeNew CFO Aaron Bloomer also appointed as Principal Accounting Officer at ResMed.Chief accounting officer change
Extracted by Autobound
From the Signal API record- Signal
- 8-K: Restructuring
What this signalsFilings often name leadership changes, deals and spending plans.
- Form
- 8-K
- Filed
- Apr 30, 2026
More from ResMed
- PatentsResMed Pty Ltd's patent output is accelerating: 98 grants in the past year, 11 in the past 30 days.Patents
- Asset saleFrazier Healthcare Acquires MatrixCare, Appoints Lujan CEOAsset sale
- GlassdoorCustomer service representative describes daily work grind at ResMedGlassdoor
- 8-KResMed divests MatrixCare business to fund $450M accelerated share repurchase.8-K
- Partnership23XI Racing NASCAR Driver Tyler Reddick Reveals Sleep Apnea Diagnosis, Teams Up with Resmed to Help Others Recognize the SignsPartnership
- Website changesResmed added or exposed lead-generation and customer-qualification tools, including a lead-generation form stylesheet and a quiz stylesheet.Website changes
More 8-K signals at other companies
- SEC 8-K4D Molecular Therapeutics, Inc.4D Molecular Therapeutics initiates Phase 3 trial directly challenging competitor drug aflibercept.SEC 8-K
- SEC 8-KAdeia Inc.Adeia Inc. appoints new CEO Dipti Vachani, effective October 12, 2026, replacing outgoing CEO Paul E. Davis.SEC 8-K
- SEC 8-KAdicet Bio, Inc.Adicet Bio launching pivotal clinical trial in Q4 2026 after positive Phase 1 data for Prula-cel.SEC 8-K
The full record
From the Signal API recordNumbers
- Dollar figure
- $3.3M (New CFO's initial long-term performance equity grant)
- Percent
- 80% (New CFO's annual short-term cash incentive bonus target as a percentage of base salary)
Details
- CIK
- 943819
- Accession number
- 0001193125-26-197282
- Timeframe
- Immediate
- Filing year
- 2026
- Why it matters
- Change management needs
- Signal category
- Workforce
Topics and mentions
Regions named
- San Diego
Extraction
- Confidence
- High
- Relevance
- 95%
- Sentiment
- Neutral
- Detected
- May 5, 2026
- signal_type
sec-8k- signal_subtype
restructuring
Use this data
Get every 8-K signal for ResMed and the companies you sell to, in the tools you already use.
Ask Claude about it
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at ResMed this week?”
Send it to your own tools
The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Try it free
Sign up and spend your free credits on the companies you sell to.
Start Free1,000 free credits
The API returns more than this page shows
This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the API
Signal
signal_nameValue in the APIassociationValue in the API
Start Free1,000 free creditsUse it in Claude via MCP
Show the full JSONHide the full JSONThe record on this page and the API request
GET /v1/signals/f5f7e78e-f21b-4fb0-8fcd-a420156adcdf returns this record as JSON. POST /v1/companies/enrich returns every signal for resmed.com.
{
"signal_id": "f5f7e78e-f21b-4fb0-8fcd-a420156adcdf",
"signal_type": "sec-8k",
"signal_subtype": "restructuring",
"detected_at": "2026-05-05T08:48:16.253+00:00",
"company": {
"name": "ResMed",
"domain": "resmed.com"
},
"data": {
"detail": "The appointment of a new CFO creates a significant opportunity for vendor review, as new financial leaders often evaluate existing systems, processes, and consulting relationships within the first 90-180 days. Mr. Bloomer's background at large corporations like Baxter and 3M suggests he may drive strategic shifts or technology investments in ResMed's finance function.",
"metrics": {
"pct": 0.8,
"timeframe": "immediate",
"pct_context": "New CFO's annual short-term cash incentive bonus target as a percentage of base salary",
"dollar_context": "New CFO's initial long-term performance equity grant",
"dollar_millions": 3.3
},
"summary": "ResMed appoints new CFO Aaron Bloomer, effective May 4, 2026, replacing retiring CFO.",
"excerpts": "On April 30, 2026, the Company also announced it appointed Aaron Bloomer, age 40, as Chief Financial Officer, effective May 4, 2026.",
"relevance": 0.95,
"sentiment": "neutral",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/943819/000119312526197282/d50610d8k.htm",
"filing_date": "2026-04-30",
"filing_year": 2026,
"sales_relevance": "Change management needs",
"signal_category": "workforce",
"regions_mentioned": [
"San Diego"
]
}
}
curl https://signals.autobound.ai/v1/signals/f5f7e78e-f21b-4fb0-8fcd-a420156adcdf \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"resmed.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.